The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatment

Simple item page
dc.contributor.authorMarcellin, Patrick
dc.contributor.authorBonino, Ferruccio
dc.contributor.authorLau, George
dc.contributor.authorFarci, Patrizia
dc.contributor.authorYurdaydin, C.
dc.contributor.authorPiratvisuth, Teerha
dc.contributor.authorJin, R.
dc.contributor.authorHadziyannis, Stephanos J.
dc.contributor.authorLu, Zhimeng
dc.contributor.authorPopescu, Madalina
dc.contributor.buuauthorGürel, Selim
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Gastroenteroloji Bilim Dalı.tr_TR
dc.date.accessioned2022-11-01T06:35:41Z
dc.date.available2022-11-01T06:35:41Z
dc.date.issued2006
dc.descriptionBu çalışma, 26-30 Nisan 2006 tarihleri arasında Vienna[Avusturya]’da düzenlenen 41. Annual Meeting of the European-Association-for-the-Study-of-the-Liver’da bildiri olarak sunulmuştur.tr_TR
dc.description.sponsorshipEuropean Assoc Study Liveren_US
dc.identifier.citationMarcellin, P. vd. (2006). ''The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatment''. Journal of hepatology, 44(Suplement 2), S275-S275.en_US
dc.identifier.endpageS275tr_TR
dc.identifier.issn0168-8278
dc.identifier.issueSupplement 2en_US
dc.identifier.startpageS275tr_TR
dc.identifier.urihttps://doi.org/10.1016/S0168-8278(06)80744-0
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0168827806807440
dc.identifier.urihttp://hdl.handle.net/11452/29287
dc.identifier.volume44tr_TR
dc.identifier.wos000237328100744tr_TR
dc.indexed.wosSCIEen_US
dc.indexed.wosCPCISen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.collaborationYurt dışıtr_TR
dc.relation.collaborationYurt içitr_TR
dc.relation.journalJournal of hepatologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararasıtr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGastroenterology & hepatologyen_US
dc.subject.wosGastroenterology & hepatologyen_US
dc.titleThe majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS (R)] sustain responses 2 years post-treatmenten_US
dc.typeMeeting Abstract
dc.wos.quartileQ1en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science